AustralianSuper related stories
All articles and analysis
Fund Briefs May 18, 2015A recap of recent venture-related fundraisings and filings; plus tables and data on closings worldwide
Brandon Capital MRCF fund raises $154.4 mlnBrandon Capital said Monday that its Medical Research Commercialisation Fund closed at AU$200 million (US$154.4 million). Existing MRCF Investors AustralianSuper and Statewide Super participated. Hesta, an existing investor in Brandon funds, took part as well HOSTPLUS. Around AU$50M of the new fund will be reserved for 20 to 30 very early seed stage investments in biotech or medical device technologies.
- LP Radar - December 2014
See the latest private equity LP updates, including allocation changes and people moves.
- Australia’s Medical Research Commercialisation Fund invests in Auspherix
Auspherix Pty Ltd said Thursday it has secured another AU$1 million (US$878,215) in a series A financing from Australia’s Medical Research Commercialisation Fund. Auspherix, of Sydney, is an early stage anti-infectives company developing antibiotics to treat resistant bacterial disease.
- Irish biotech firm Heart Metabolics snags $20 mln Series A funds
Heart Metabolics said Thursday that it has closed $20 million in Series A funding. The investors were venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. Based in Dublin, Ireland, Heart Metabolics is a biotech firm focused on developing treatments for cardio-metabolic diseases.
- Report: Quadrant raises A$850m Australia fund(2)
The Sydney-based firm closed its seventh vehicle oversubscribed after one month in the market.
- Report: Quadrant raises A$850m Australia fund
The Sydney-based firm closed its seventh vehicle oversubscribed after one month in the market.
- Brookfield hires ex-RREEF Asia head Thassim(2)
The global alternative asset manager has appointed Niel Thassim as head of Asia for its Private Funds Group to drive fundraising for private investment vehicles across its asset classes.
- MRCF invests in antibiotics start-up Auspherix
Auspherix, an early stage anti-infectives company has launched with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund. Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney, emerging from research led by Professor Ian Charles, director of the ithree institute together with Dr Dagmar Alber, ithree Senior Research Fellow.
- Brookfield hires ex-RREEF Asia head Thassim
The global alternative asset manager has appointed Niel Thassim as head of Asia for its Private Funds Group to drive fundraising for private investment vehicles across its asset classes.